A Unique Drug Distribution Process for Radium Ra 223 Dichloride Injection and Its Implication for Product Quality,Patient Privacy,and Delineation of Professional Responsibilities
Restricted accessResearch articleFirst published online November, 2014
A Unique Drug Distribution Process for Radium Ra 223 Dichloride Injection and Its Implication for Product Quality,Patient Privacy,and Delineation of Professional Responsibilities
On May 15, 2013, Bayer Healthcare Pharmaceuticals announced that it had received marketing approval for the therapeutic radioactive medication radium Ra 223 dichloride injection (Xofigo; Ra 223). The product acquisition and distribution process for hospital-based nuclear pharmacies and nuclear medicine services is unlike any other. The product is distributed as a low-risk compounded sterile preparation through a single compounding nuclear pharmacy located in Denver, Colorado, pursuant to a prescription. This model for drug distribution and delivery to the user institution has implications for product quality, patient privacy, and delineation of professional responsibilities.
Pharmaceutical compounding-sterile preparations. In: United States Pharmacopeia 35th Revision and The National Formulary, 30th edition. Rockville, MD: US Pharmacopeial Convention; 2011:chap 797.
4.
Xofigo Radium Ra 223 Dichloride Injection Storage and Handling Guide. Wayne, NJ: Bayer Healthcare Pharmaceuticals.
